Novavax
NVAX
253 hedge funds and large institutions have $660M invested in Novavax in 2022 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 88 increasing their positions, 63 reducing their positions, and 96 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 63
2.88% more ownership
Funds ownership: 43.44% → 46.32% (+2.9%)
17% less call options, than puts
Call options by funds: $121M | Put options by funds: $146M
22% less funds holding
Funds holding: 325 → 253 (-72)
62% less capital invested
Capital invested by funds: $1.75B → $660M (-$1.09B)
73% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 96
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$38.2M |
| 2 |
State Street
Boston,
Massachusetts
|
+$29.8M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$26.3M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
+$21M |
| 5 |
N
Natixis
Paris,
France
|
+$16.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Coatue Management
New York
|
-$30.1M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$25.6M |
| 3 |
Millennium Management
New York
|
-$14.8M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$12.3M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$10.5M |
NVAX Hedge Fund Activity: Q3 2022 in Review
253 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Novavax (NVAX) for Q3 2022, worth a combined $660M — down 62% from $1.75B a quarter earlier.
Sellers outnumbered buyers: 96 funds closed out of NVAX and 26 opened new positions — a net loss of 70 holders — while 63 trimmed existing stakes and 88 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $38.2M. The largest seller was Coatue Management, cutting an estimated $30.1M.
- 253 institutional investors held Novavax (NVAX) as of Q3 2022, down from 325 in Q2 2022.
- Funds reported $660M of Novavax stock for Q3 2022, down 62% quarter-over-quarter.
- 26 funds opened new Novavax positions in Q3 2022 and 96 closed out, a net change of -70 holders.
- The largest Novavax buyer in Q3 2022 was Renaissance Technologies, an estimated $38.2M added.
- The largest Novavax seller in Q3 2022 was Coatue Management, an estimated $30.1M sold.
Based on aggregated 13F filings for Q3 2022.